Agenus Inc. (AGEN)

Compare

3.8000

+0.2600

+(7.34%)

At close: January 31 at 4:00:01 PM EST

3.8299

+0.03

+(0.79%)

After hours: 7:32:31 PM EST

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

LEXINGTON, Mass., January 29, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.

Business Wire 3 days ago

AGEN
+7.34%
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

LEXINGTON, Mass., January 22, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. Data from five presentations underscore the transformative potential of BOT/BAL across multiple lines of therapy in colorectal cancer, including neoadjuvant, first-line, and refractory settings. Data presented also highlight BOT/BAL’

Business Wire 10 days ago

AGEN
+7.34%
What Makes Agenus (AGEN) a New Buy Stock

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 12 days ago

AGEN
+7.34%
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Here is how Agenus (AGEN) and Abbott (ABT) have performed compared to their sector so far this year.

Zacks 12 days ago

AGEN
+7.34%
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

LEXINGTON, Mass., December 18, 2024--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium. The conference will take place on January 23-25, 2025, in San Francisco, California.

Business Wire last month

AGEN
+7.34%
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B

The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut spending and the U.S. PTO withdrew a controversial proposed patent rule.

BioPharma Dive last month

AMGN

AGEN
+7.34%
AZN
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

LEXINGTON, Mass., December 05, 2024--Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. This initiative follows the successful closing of a $22 million mortgage secured by key real estate assets, providing the compa

Business Wire last month

AGEN
+7.34%
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development

Agenus Inc. (NASDAQ:AGEN) shares are trading higher in the morning session on Wednesday. The company has secured a $22 million non-amortizing mortgage, backed by its Berkeley-based Biologics CMC facility and its 66-acre biomanufacturing-zoned property in Vacaville, California. The deal, facilitated by L&L Capital, provides $20 million in net proceeds after closing costs and interest reserve, boosting Agenus’ cash position ahead of anticipated further cash infusions in the coming months. The mort

Benzinga 2 months ago

AGEN
+7.34%
Agenus Secures $22 Million Mortgage, Plans Operational Realignment; Shares Jump

Agenus (AGEN) said Wednesday it has secured a $22 million mortgage backed by two California properti

PREMIUM
MT Newswires 2 months ago

AGEN
+7.34%
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

LEXINGTON, Mass., November 27, 2024--Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-zoned property in Vacaville, California. Facilitated by L&L Capital, the transaction yields $20 million in net proceeds after closing costs and interest reserve, bolstering the company’s cash posi

Business Wire 2 months ago

AGEN
+7.34%
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Agenus (AGEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 2 months ago

AGEN
+7.34%
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 2 months ago

AGEN
+7.34%
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround

Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 2 months ago

AGEN
+7.34%
Q3 2024 Agenus Inc Earnings Call

Q3 2024 Agenus Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

AGEN
+7.34%
Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ...

Agenus Inc (AGEN) reports progress in cancer treatment trials amid financial constraints and strategic partnership discussions.

GuruFocus.com 2 months ago

AGEN
+7.34%
Agenus (AGEN) Q3 2024 Earnings Call Transcript

AGEN earnings call for the period ending September 30, 2024.

Motley Fool 2 months ago

AGEN
+7.34%
Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -50.95% and 35.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

AGEN
+7.34%
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

LEXINGTON, Mass., November 12, 2024--Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024.

Business Wire 2 months ago

AGEN
+7.34%
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

LEXINGTON, Mass., November 07, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D.,

Business Wire 2 months ago

AGEN
+7.34%
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

LEXINGTON, Mass., November 05, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Business Wire 2 months ago

AGEN
+7.34%

Performance Overview

Return	AGEN	S&P 500
YTD	+41.26%	+2.26%
1-Year	-69.84%	+22.65%
3-Year	-92.64%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Agenus Inc. (AGEN)

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

What Makes Agenus (AGEN) a New Buy Stock

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development

Agenus Secures $22 Million Mortgage, Plans Operational Realignment; Shares Jump

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround

Q3 2024 Agenus Inc Earnings Call

Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ...

Agenus (AGEN) Q3 2024 Earnings Call Transcript

Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Performance Overview